NCT02829034CompletedPhase 4
A Randomized, Double-blind, Placebo Controlled, Multi-center Study to Assess the Effect of Ranolazine in Subjects With Pulmonary Hypertension and Right Ventricular Dysfunction Using Cardiovascular MRI
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- University of Pennsylvania
- Enrollment
- 22
- Locations
- 3
- Primary Endpoint
- Absolute Change From Baseline Right Ventricular Ejection Fraction (the Unit is Percentage)
Study Overview
Brief Summary
This study is looking to see if giving ranolazine to subjects on stable pulmonary hypertension therapies but with right ventricular dysfunction (RVEF <45%) will improve their health by improving right ventricular (RV) function.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Symptomatic pulmonary hypertension based on one of the following criteria:
- •Idiopathic pulmonary arterial hypertension
- •Familial pulmonary arterial hypertension
- •Pulmonary hypertension associated with connective tissue disease
- •Chronic thromboembolic pulmonary hypertension-nonsurgical/distal vessel disease or patients who are reluctant to go to surgery within a 6-month period and are willing to participate
- •Simple congenital such as repaired atrial septal defect or ventricular septal defect or unrepaired small atrial septal defect or ventricular septal defect with persistent and out of proportion pulmonary arterial hypertension
- •Group 3 patients who have a component of pulmonary arterial hypertension *Pulmonary hypertension caused by conditions affect the veins and small vessels of the lungs
- •Sickle cell disease
- •Group 5 pulmonary hypertension such as polycythemia vera
- •Essential thrombocythemia
- •Sarcoidosis
- •Vasculitis
- •Metabolic disorder
- •World Health Organization functional class II, III, or IV
- •Mean pulmonary artery pressure >25 mmHg at rest
- •Pulmonary capillary wedge pressure or left ventricular end diastolic pressure < 15 mmHg
- •Pulmonary vascular resistance > 3 mmHg/L/min
- •Right ventricle ejection fraction < 45%
- •6-minute walk test distance > 50 meters
Exclusion Criteria
- •Previous treatment with or prior sensitivity to ranolazine
- •Any family history of corrected QT interval prolongation, congenital long QT syndrome, or receiving drugs that prolong the corrected QT interval
- •Parenchymal lung disease showing total lung capacity < 50% of predicted OR forced expiratory volume at one second/forced vital capacity < 50%
- •Portal hypertension associated with chronic liver disease
- •Left sided heart disease including any of the following: moderate or greater aortic or mitral valve disease, Any left ventricle cardiomyopathy, Left ventricular systolic dysfunction defined as an ejection fraction < 50%, Symptomatic coronary artery disease
- •Uncontrolled systemic hypertension
- •Implantable cardioverter-defibrillator, Pacemaker, hazardous metallic implants or any other contraindication to MRI.
Arms & Interventions
Ranolazine
Active Comparator
Ranolazine 500mg by mouth twice per day and after two weeks increase to 1000mg by mouth twice per day
Intervention: Ranolazine (Drug)
Placebo
Placebo Comparator
Placebo by mouth twice per day
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
Absolute Change From Baseline Right Ventricular Ejection Fraction (the Unit is Percentage)
Time Frame: 26 weeks
Change in right ventricle ejection fraction as assessed by MRI
Secondary Outcomes
- Percent Change in 6min-walk-test Distance(6 months)
- Change in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP)(6 months)
Investigators
Study Sites (3)
Loading locations...
Similar Trials
Completed
Phase 4
Targeting the Right Ventricle in Pulmonary HypertensionPulmonary HypertensionNCT01839110University of Pennsylvania22
Terminated
Phase 2
Revatio Portal-Pulmonary Arterial Hypertension TrialPortopulmonary HypertensionNCT01517854University Health Network, Toronto12
Completed
Phase 2
Safety and Effectiveness of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary DiseasePulmonary HypertensionNCT00345774Epix Pharmaceuticals, Inc.72
Active, not recruiting
Phase 2
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPDPulmonary HypertensionChronic Obstructive Pulmonary DiseaseNCT05612035Merck Sharp & Dohme LLC129
Completed
Phase 4
A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial HypertensionPulmonary Arterial HypertensionPulmonary HypertensionNCT00058929United Therapeutics39
